Investigational AstraZeneca vaccine prevents COVID-19 eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Antibody Mediated Prevention (AMP) trials data published by the
New England Journal of Medicine
Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains
Public Relations Pacific LLC
E-Mail
SEATTLE - (EMBARGOED UNTIL MARCH 17, 2021, AT 5 P.M. ET) - The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb. This finding was seen both in Sub-Saharan Africa and the U.S. and South America. VRCO1 did not prevent the acquisition of HIV to strains that were resistant to the bNAb. As the resistant strains constituted nearly 70% of the circulating strains in these regions, there was no difference noted between the VRC01 arms and placebo arm in terms of overall prevention of HIV acquisition. The sensitivity to bNAbs was assessed by a laborat
Cell and Gene Therapy Portfolio Builder ElevateBio Raises $525M in Financing
Cell and gene therapy company ElevateBio has completed a $525 million Series C financing, with plans to use the proceeds toward developing and expanding its technology platforms, growing its network of process development and GMP manufacturing capacity, advancing industry partnerships, and continuing to develop candidates through its portfolio of companies. [ElevateBio]
March 15, 2021
Cell and gene therapy company ElevateBio has completed a $525 million Series C financing, with plans to use the proceeds toward developing and expanding its technology platforms, growing its network of process development and GMP manufacturing capacity, advancing industry partnerships, and continuing to develop candidates through its portfolio of companies. [ElevateBio]
Dive Brief:
Elevate Bio, a well-funded biotech startup led by former Alexion Pharmaceuticals executives, has raised another $525 million in venture funding to fuel expansion of an unusual business model that blends in-house research with a technology platform meant to advance the work of Elevate s partners.
Elevate s focus is cell and gene therapy, a fast-growing field that it aims to accelerate by offering companies access to centralized research and manufacturing resources. So far, Elevate is partnered with Allovir, HighPassBio and LifeEDIT Therapeutics, and has formed a 10-year alliance with Massachusetts General Hospital.
The $525 million in new funding is a particularly rich Series C financing, and follows two earlier venture rounds that raised a combined $320 million.